The effect of a continuous regimen of drospirenone 3 mg/ethinylestradiol 30 microg on Cox-2 and Ki-67 expression in the endometrium

Hugo Maia, Julio Casoy, Júlio Casoy, Célia Athayde, Jorge Valente Filho, Elsimar M Coutinho, Elsimar Metzker Coutinho
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2010 · vol. 15(1) , pp. 35–40 · doi:10.3109/13625180903383928 · PMID:20063991 · W2036181634
Other OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study found that drospirenone 3 mg/ethinylestradiol 30 μg inhibited endometrial Cox-2 and Ki-67 expression, with increased Cox-2 associated with bleeding patterns and discontinuation of use.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To study Cox-2 expression in relation to bleeding patterns in patients using an oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinylestradiol (DRSP/EE). METHODS: Forty-three patients of reproductive age with symptoms of menorrhagia and dysmenorrhoea, who were submitted to endometrial resection, were enrolled. Twelve patients were in the proliferative phase and the remaining 31 were either currently using DRSP/EE or had discontinued its use four to eight days prior to hysteroscopy. Cox-2 and Ki-67 expression were determined in the endometrium using immunohistochemistry. RESULTS: Cox-2 expression was significantly inhibited in the glandular epithelium of patients who became amenorrhoeic during DRSP/EE use; however, in patients with breakthrough bleeding and in those who had stopped oral contraceptive use, a significant increase occurred in Cox-2 expression in the endometrium. Ki-67 expression decreased significantly during DRSP/EE use, but returned to proliferative phase values four to eight days after discontinuation of treatment. CONCLUSION: These results suggest that endometrial bleeding during DRSP/EE use is associated with an increase in Cox-2 expression in the endometrium. A similar increase was also seen four to eight days following discontinuation of the oral contraceptive.

My notes (saved in your browser only)

Condition tags

dysmenorrhea

MeSH descriptors

Androstenes Contraceptives, Oral, Synthetic Cyclooxygenase 2 Endometrium Estrogens Ethinyl Estradiol Ki-67 Antigen Mineralocorticoid Receptor Antagonists Adult Androstenes Androstenes Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Cyclooxygenase 2 Dose-Response Relationship, Drug Endometrium Endometrium Endometrium Estrogens Estrogens

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (19)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-11T05:50:48.314143+00:00
pubmed
last seen: 2026-10-08T21:07:11.085580+00:00
unpaywall
last seen: 2026-10-16T06:24:35.758740+00:00
License: CC0 · commercial use OK